Viridian Therapeutics Share Price (NASDAQ: VRDN)

$18.39

▲

-0.05

(-0.27%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Viridian Therapeutics Stock chart to analyse performance

Viridian Therapeutics stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$18.04
Today's High:$18.49
$18.39
1.9%
Downside
Day's Volatility :2.43%
Upside
0.54%
52 Weeks Low:$9.90
52 Weeks High:$27.20
$18.39
46.17%
Downside
52 Weeks Volatility :63.6%
Upside
32.39%

Viridian Therapeutics Stock Returns

Period	Viridian Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	31.64%	3.6%	0.0%
6 Months	27.62%	-7.7%	0.0%
1 Year	27.09%	-12.6%	0.0%
3 Years	-13.3%	9.5%	-4.7%

Viridian Therapeutics Inc Key Stats

Check Viridian Therapeutics key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$18.44
Open	$18.49
Today's High	$18.49
Today's Low	$18.04
Market Capitalization	$1.5B
Today's Volume	$649.7K
52 Week High	$27.2
52 Week Low	$9.9
Revenue TTM	$305.0K
EBITDA	$-371.1M
Earnings Per Share (EPS)	$-3.57
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-65.88%

Stock Returns calculator for Viridian Therapeutics Stock including INR - Dollar returns

The Viridian Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Viridian Therapeutics investment value today

Current value as on today

₹1,30,557

Returns

₹30,557

(+30.56%)

Returns from Viridian Therapeutics Stock

₹25,272 (+25.27%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Viridian Therapeutics Stock

-33%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Viridian Therapeutics Stock from India on INDmoney has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Viridian Therapeutics Inc

Name
Holdings %
Name
Holdings %
FMR Inc
14.97%
BlackRock Inc
6.99%
Deep Track Capital, LP
6.59%
COMMODORE CAPITAL LP
5.97%
Vanguard Group Inc
5.52%
Kynam Capital Management, LP
5.42%

Analyst Recommendation on Viridian Therapeutics Stock

Rating

Trend

Buy

95%Buy

4%Hold

0%Sell

Based on 21 Wall street analysts offering stock ratings for Viridian Therapeutics(by analysts ranked 0 to 5 stars)

Viridian Therapeutics Share Price Target

What analysts predicted

Upside of 108.81%

Target:

$38.40

Current:

$18.39

Viridian Therapeutics share price target is $38.40, a slight Upside of 108.81% compared to current price of $18.39 as per analysts' prediction.

Viridian Therapeutics Stock Insights

Price Movement
In the last 7 days, VRDN stock has moved down by -4.3%
Increasing Revenue
Revenue is up for the last 2 quarters, 72.0K → 75.0K (in $), with an average increase of 4.0% per quarter
Decreasing Net Profit
Netprofit is down for the last 6 quarters, -48.54M → -100.73M (in $), with an average decrease of 16.2% per quarter
VRDN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 44.6%
VRDN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 127.9%
Price to Sales
ForVRDN every $1 of sales, investors are willing to pay $4597.5, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Viridian Therapeutics Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$4.5M	↓ 46.8%
Net Income	$-42.4M	↑ 29.71%
Net Profit Margin	-950.91%	↓ 560.94%

	FY20	Y/Y Change
Revenue	$1.1M	↓ 76.46%
Net Income	$-111.0M	↑ 161.63%
Net Profit Margin	-10.6K%	↓ 9618.99%

	FY21	Y/Y Change
Revenue	$3.0M	↑ 182.19%
Net Income	$-79.4M	↓ 28.44%
Net Profit Margin	-2.7K%	↑ 7889.64%

	FY22	Y/Y Change
Revenue	$1.8M	↓ 40.2%
Net Income	$-125.4M	↑ 57.96%
Net Profit Margin	-7.1K%	↓ 4398.97%

	FY23	Y/Y Change
Revenue	$314.0K	↓ 82.28%
Net Income	$-237.7M	↑ 89.51%
Net Profit Margin	-75.7K%	↓ 68632.23%

	FY24	Y/Y Change
Revenue	$302.0K	↓ 3.82%
Net Income	$-269.9M	↑ 13.55%
Net Profit Margin	-89.4K%	↓ 13675.63%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$72.0K	↑ 0.0%
Net Income	$-48.5M	↓ 27.4%
Net Profit Margin	-67.4K%	↑ 25441.67%

	Q2 FY24	Q/Q Change
Revenue	$72.0K	↑ 0.0%
Net Income	$-65.0M	↑ 33.89%
Net Profit Margin	-90.3K%	↓ 22848.62%

	Q3 FY24	Q/Q Change
Revenue	$86.0K	↑ 19.44%
Net Income	$-76.7M	↑ 18.0%
Net Profit Margin	-89.2K%	↑ 1094.8%

	Q4 FY24	Q/Q Change
Revenue	$72.0K	↓ 16.28%
Net Income	$-79.7M	↑ 3.96%
Net Profit Margin	-110.7K%	↓ 21555.91%

	Q1 FY25	Q/Q Change
Revenue	$72.0K	↑ 0.0%
Net Income	$-86.9M	↑ 9.01%
Net Profit Margin	-120.7K%	↓ 9981.94%

	Q2 FY25	Q/Q Change
Revenue	$75.0K	↑ 4.17%
Net Income	$-100.7M	↑ 15.9%
Net Profit Margin	-134.3K%	↓ 13602.22%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$-28.3M	↑ 28.58%

	FY20	Y/Y Change
Profit	$-27.3M	↓ 3.81%

	FY21	Y/Y Change
Profit	$2.3M	↓ 108.6%

	FY22	Y/Y Change
Profit	$1.0M	↓ 56.59%

	FY23	Y/Y Change
Profit	$-1.0M	↓ 199.12%

	FY24	Y/Y Change
Profit	$302.0K	↓ 129.96%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$-273.0K	↓ 1.8%

	Q2 FY24	Q/Q Change
Profit	$-5.7M	↑ 1994.87%

	Q3 FY24	Q/Q Change
Profit	$86.0K	↓ 101.5%

	Q4 FY24	Q/Q Change
Profit	$-51.0K	↓ 159.3%

	Q1 FY25	Q/Q Change
Profit	$72.0K	↓ 241.18%

	Q2 FY25	Q/Q Change
Profit	$75.0K	↑ 4.17%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-36.1M	↑ 34.32%
Investing Cash Flow	$28.2M	↓ 194.38%
Financing Cash Flow	$70.0K	↓ 99.83%

	FY20	Y/Y Change
Operating Cash Flow	$-29.8M	↓ 17.41%
Investing Cash Flow	$-50.5M	↓ 278.85%
Financing Cash Flow	$101.3M	↑ 144630.0%

	FY21	Y/Y Change
Operating Cash Flow	$-54.6M	↑ 83.29%
Investing Cash Flow	$-74.3M	↑ 47.17%
Financing Cash Flow	$125.3M	↑ 23.65%

	FY22	Y/Y Change
Operating Cash Flow	$-93.8M	↑ 71.92%
Investing Cash Flow	$-115.1M	↑ 54.96%
Financing Cash Flow	$322.2M	↑ 157.23%

	FY23	Y/Y Change
Operating Cash Flow	$-184.2M	↑ 96.26%
Investing Cash Flow	$-94.3M	↓ 18.13%
Financing Cash Flow	$225.7M	↓ 29.97%

	FY24	Y/Y Change
Operating Cash Flow	$-232.3M	↑ 26.14%
Investing Cash Flow	$-228.7M	↑ 142.6%
Financing Cash Flow	$457.7M	↑ 102.83%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-45.2M	↑ 19.01%
Investing Cash Flow	$-143.0M	↓ 15.71%
Financing Cash Flow	$177.1M	↓ 10.99%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-46.1M	↑ 1.85%
Investing Cash Flow	$62.0M	↓ 143.33%
Financing Cash Flow	$108.0K	↓ 99.94%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-67.7M	↑ 47.0%
Investing Cash Flow	$-84.7M	↓ 236.61%
Financing Cash Flow	$245.0M	↑ 226773.15%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-73.3M	↑ 8.31%
Investing Cash Flow	$-62.9M	↓ 25.69%
Financing Cash Flow	$35.5M	↓ 85.5%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-92.7M	↑ 26.35%
Investing Cash Flow	$100.1M	↓ 259.04%
Financing Cash Flow	$9.2M	↓ 74.07%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-75.4M	↓ 18.65%
Investing Cash Flow	$75.7M	↓ 24.33%
Financing Cash Flow	$764.0K	↓ 91.71%

Viridian Therapeutics Technicals Summary

Sell

Neutral

Buy

Viridian Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Viridian Therapeutics Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Viridian Therapeutics Inc	5.63%	27.62%	27.09%	-13.3%	73.0%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Viridian Therapeutics Inc	NA	NA	NA	-4.08	-0.66	-0.4	NA	4.0
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Viridian Therapeutics Inc	Buy	$1.5B	73.0%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Viridian Therapeutics Inc

Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases. The company's product pipeline includes veligrotug, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R monoclonal antibodies targeting IGF-1R and engineered of half-life extension technology, which is in Phase 3 clinical trial for the treatment of TED. It also develops portfolio of engineered anti-neonatal Fc receptor inhibitors, such as VRDN-006 and VRDN-008 for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Organization	Viridian Therapeutics
Employees	143
CEO	Mr. Stephen F. Mahoney J.D., MBA
Industry	Healthcare

Key Management of Viridian Therapeutics Inc

Name	Title
Mr. Stephen F. Mahoney J.D., MBA	CEO, President & Director
Mr. Seth Harmon	Chief Financial Officer
Mr. Thomas W. Beetham J.D., MBA	Chief Operating Officer
Ms. Jennifer Tousignant J.D.	Chief Legal Officer
Dr. Eric N. Olson Ph.D.	Co-Founder & Chairman of Scientific Advisory Board
Dr. Michael R. Bristow M.D., Ph.D.	Co-Founder & Member of the Scientific Advisory Board
Dr. Marvin H. Caruthers Ph.D.	Co-Founder & Scientific Advisory Board Member
Mr. Vahe Bedian Ph.D.	Co-Founder & Scientific Advisor
Ms. Melissa Manno	Chief Human Resources Officer
Mr. Anthony Casciano	Chief Commercial Officer

Important FAQs about investing in VRDN Stock from India :

What is Viridian Therapeutics share price today?

Viridian Therapeutics share price today is $18.39 as on August 30, 2025 at 1:29 am IST at the close of the market. Viridian Therapeutics share today touched a day high of $18.49 and a low of $18.04.

What is the 52 week high and 52 week low for Viridian Therapeutics share?

Viridian Therapeutics share touched a 52 week high of $27.20 and a 52 week low of $9.90. Viridian Therapeutics stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $18.39, lower by 32.39% versus the 52 week high.

How to invest in Viridian Therapeutics Stock (VRDN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Viridian Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Viridian Therapeutics Shares that will get you 0.0816 shares as per Viridian Therapeutics share price of $18.39 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Viridian Therapeutics Stock (VRDN) from India?

Indian investors can start investing in Viridian Therapeutics (VRDN) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Viridian Therapeutics stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Viridian Therapeutics share’s latest price of $18.39 as on August 30, 2025 at 1:29 am IST, you will get 0.5438 shares of Viridian Therapeutics. Learn more about fractional shares .

What are the returns that Viridian Therapeutics has given to Indian investors in the last 5 years?

Viridian Therapeutics stock has given 73.0% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?